Full
Outline
To observe the clinical efficacy of Daxianxiong Decoction（大陷胸汤）in the treatment of severe acute pancreatitis and acute lung injury.
Eighty patients with severe acute pancreatitis and acute lung injury who met the inclusion criteria for this study were randomly divided into two groups using a random number table method. The control group received symptomatic treatment with conventional western medicine，while the observation group combined with oral administration of Daxianxiong Decoction in addition. After 7 days of continuous treatment，the Murray lung injury scores and modified Marshall scores，the blood gas indexes［blood oxygen partial pressure（PaO2），blood oxygen saturation（SaO2），partial pressure of carbon dioxide（PCO2），oxygenation index］，the respiratory mechanics indexes［airway resistance（Raw），work of breath（WOB），dynamic lung compliance（Cdyn）］and the serum inflammatory indexes［C-reactive protein（CRP），tumor necrosis factor-α（TNF-α），interleukin-6（IL-6），procalcitonin（PCT）］between two groups were compared，and the total effective rate and drug safety between the two groups were compared.
After treatment，the scores of Murray lung injury and modified Marshall，the values of PaCO2，Raw and WOB，the serum levels of CRP，PCT，IL-6 and TNF-αwere all lower than those before treatment（P<0.05），and the scores，values and levels of the observation group were lower than those the control group（P<0.05）. The values of PaO2，SaO2 and oxygenation index and Cdyn were higher in both groups（P<0.05），the values of the observation group were higher than those of the control group（P<0.05）. The total effective rate of the observation group（92.5%）was higher than the control group（75.0%）（P<0.05）. There were no adverse reactions related to medication during the treatment in both groups.
The application of Daxianxiong Decoction can reduce serum inflammatory cytokine levels，improve respiratory mechanical parameters and increase oxygen partial pressure and blood oxygen levels in patients with severe acute pancreatitis and acute lung injury，which help to alleviate organ damage in patients with definite therapeutic effects.
34
15
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |
关闭全屏
No. 86 Xueyuan South Road, Haidian District, Beijing
010-62662699(Operation and Technical Support)
qkjq@cast.org.cn
Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House
